Difluzol 150 mg capsules, No. 2

In stock: 3
$60.00

Composition

Active ingredient: fluconazole;

1 capsule contains 150 mg of fluconazole, calculated as 100% active ingredient;

excipients: calcium stearate, sodium starch glycolate (type A);

Capsule shell composition: gelatin, Patent Blue V (E131), Quinoline Yellow (E104), titanium dioxide (E171).

Dosage Form

Capsules.

Main physical and chemical properties: hard gelatin capsules No. 1, turquoise-colored body, green-colored cap.

Capsule contents: white or nearly white, odorless powder.

Pharmacotherapeutic group

Antifungal agents for systemic use. Triazole derivatives. ATC code J02A C01.

Pharmacological Properties

Pharmacodynamics.

Mechanism of action.

Fluconazole is an antifungal agent of the triazole class. Its primary mechanism of action is the inhibition of fungal 14-alpha-lanosterol demethylation, mediated by cytochrome P450, which is an essential step in the biosynthesis of fungal ergosterol. The accumulation of 14-alpha-methyl-sterols correlates with the subsequent loss of ergosterol through the fungal cell membrane and may account for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.

Administration of fluconazole at a dose of 50 mg daily for 28 days does not affect plasma testosterone levels in men or endogenous steroid levels in women of reproductive age. Fluconazole at a dose of 200–400 mg per day has no clinically significant effect on endogenous steroid levels or on the response to adrenocorticotropic hormone (ACTH) in healthy male volunteers.

Interaction studies with antipyrine have shown that a single or repeated dose of 50 mg of fluconazole does not affect the metabolism of antipyrine.

In vitro susceptibility.

In vitro, fluconazole exhibits antifungal activity against the most common Candida species (including C. albicans, C. parapsilosis, and C. tropicalis). C. glabrata exhibits a wide range of susceptibility to fluconazole, whereas C. krusei is resistant to it.

Fluconazole also demonstrates in vitro activity against both Cryptococcus neoformans and Cryptococcus gattii, as well as against the endemic molds Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and Paracoccidioides brasiliensis.

Relationship between pharmacokinetic and pharmacodynamic properties.

According to the results of animal studies, there is a correlation between the minimum inhibitory concentration and efficacy against experimental models of mycoses caused by Candida species. According to the results of clinical studies, there is a linear relationship between AUC and the dose of fluconazole (approximately 1:1). There is also a direct, but insufficient, relationship between AUC or dose and a positive clinical response to treatment of oral candidiasis and, to a lesser extent, candidemia. Similarly, treatment of infections caused by strains against which fluconazole exhibits a high minimum inhibitory concentration is less satisfactory.

Mechanism of Resistance.

Microorganisms of the genus Candida exhibit numerous mechanisms of resistance to azole antifungals. Fluconazole exhibits a high minimum inhibitory concentration against fungal strains that possess one or more resistance mechanisms, which negatively affects its efficacy in vivo and in clinical practice. Cases of superinfection with Candida spp. other than C. albicans have been reported; these species are often resistant to fluconazole (e.g., Candida krusei). Alternative antifungal agents should be used to treat such cases.

Breakpoints (in accordance with the recommendations of the European Committee on Antimicrobial Susceptibility Testing).

Based on pharmacokinetic/pharmacodynamic studies, in vitro susceptibility testing, and clinical response, breakpoints for fluconazole against microorganisms of the genus Candida were established. These have been divided into species-unrelated breakpoints, which were largely determined based on pharmacokinetics/pharmacodynamics and are independent of species-specific minimum inhibitory concentration (MIC) values, and species-specific breakpoints, which are most commonly associated with infections in humans. These breakpoints are listed below.

Antifungal Agent
Species-specific cut-off values
S ≤ / R >
Species-independent cut-off points
S ≤ / R >
Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
Fluconazole
2/4
IE
  • -
2/4
2/4
2/4

S = sensitive.

R = resistant.

a Species-independent breakpoints, which were largely determined based on pharmacokinetics/pharmacodynamics and do not depend on species-specific minimum inhibitory concentration (MIC) values. They were studied only in microorganisms for which no specific control point exists.

  • - Susceptibility testing is not recommended because the specified species is not the target of drug therapy.

IE – There is insufficient evidence to determine whether the specified species is the target of drug therapy.

Pharmacokinetics.

The pharmacokinetic properties of fluconazole are similar following intravenous and oral administration.

Absorption.

Fluconazole is well absorbed following oral administration, and plasma concentrations and systemic bioavailability exceed 90% of the plasma fluconazole levels achieved with intravenous administration. Concomitant food intake does not affect the absorption of the drug when administered orally. Peak plasma concentration is reached 0.5–1.5 hours after administration. Plasma concentrations of the drug are proportional to the dose. Steady-state concentrations of 90% are reached on the second day of treatment when a loading dose twice the usual daily dose is administered on the first day.

Distribution.

The volume of distribution is approximately equal to the total body fluid volume. Plasma protein binding is low (11–12%).

Fluconazole penetrates well into all body fluids studied. Fluconazole levels in saliva and sputum are similar to plasma concentrations. In patients with fungal meningitis, the concentration of fluconazole in cerebrospinal fluid reaches 80% of the plasma concentration.

High concentrations of fluconazole in the skin, exceeding serum levels, are achieved in the stratum corneum, epidermis, dermis, and sweat. Fluconazole accumulates in the stratum corneum. When administered at a dose of 50 mg once daily, the concentration of fluconazole after 12 days of treatment was 73 μg/g, and 7 days after the end of treatment, the concentration was still 5.8 μg/g. When administered at a dose of 150 mg once weekly, the concentration of fluconazole on the 7th day of treatment was 23.4 μg/g; 7 days after the next dose was administered, the concentration was still 7.1 μg/g.

The concentration of fluconazole in the nails after 4 months of treatment with 150 mg once weekly was 4.05 μg/g in healthy volunteers and 1.8 μg/g in patients with nail disorders; fluconazole was detected in nail samples 6 months after completion of therapy.

Biotransformation.

Fluconazole is metabolized to a minor extent. Following administration of a dose labeled with radioactive isotopes, only 11% of fluconazole is excreted in the urine in a metabolized form. Fluconazole is a selective inhibitor of the CYP2C9 and CYP3A4 isoenzymes, as well as an inhibitor of the CYP2C19 isoenzyme.

Elimination.

The half-life of fluconazole in plasma is approximately 30 hours. Most of the drug is excreted by the kidneys, with 80% of the administered dose appearing in the urine unchanged. The clearance of fluconazole is proportional to creatinine clearance. No circulating metabolites have been detected.

The drug’s long half-life in blood plasma allows for a single-dose regimen in the treatment of vaginal candidiasis, as well as once-weekly dosing for other indications.

Renal impairment.

In patients with severe renal insufficiency (glomerular filtration rate < 20 mL/min), the half-life increases from 30 hours to 98 hours. Therefore, the dose of fluconazole must be reduced in this patient population. Fluconazole is removed by hemodialysis and, to a lesser extent, by intraperitoneal dialysis. A 3-hour hemodialysis session reduces plasma fluconazole levels by approximately 50%.

Elderly patients.

Changes in pharmacokinetics in elderly patients appear to depend on renal function.

Indications

Difluzol® is indicated for the treatment of the following fungal infections in adults (see the “Pharmacodynamics” section):

  • Acute vaginal candidiasis, when local therapy is not appropriate.
  • Candidal balanitis, when topical therapy is not appropriate.

Treatment with Difluzol® may be initiated prior to receiving the results of culture and other laboratory tests; however, once the test results are available, antifungal therapy should be adjusted accordingly.

Official recommendations regarding the appropriate use of antifungal agents should be taken into account.

Contraindications

  • Hypersensitivity to fluconazole, other azole compounds, or to any of the drug’s excipients.
  • Concomitant use of fluconazole and terfenadine in patients receiving fluconazole repeatedly at doses of 400 mg/day or higher (based on the results of a multiple-dose interaction study).
  • Concomitant use of fluconazole and other drugs that prolong the QT interval and are metabolized by the CYP3A4 enzyme (e.g., cisapride, astemizole, pimozide, quinidine, and erythromycin).

Interactions with Other Medications and Other Types of Interactions

The concomitant use of fluconazole and the drugs listed below is contraindicated.

Cisapride: Adverse cardiac reactions, including paroxysmal ventricular tachycardia of the “pirouette” type, have been reported in patients receiving concomitant fluconazole and cisapride. A controlled study demonstrated that the concomitant use of 200 mg of fluconazole once daily and 20 mg of cisapride four times daily resulted in a significant increase in cisapride plasma levels and QT interval prolongation. Concomitant use of fluconazole and cisapride is contraindicated (see the “Contraindications” section).

Terfenadine: Due to cases of severe cardiac arrhythmias caused by QTc prolongation, in patients who took azole antifungal medications concomitantly with terfenadine, studies were conducted to evaluate the interaction between these drugs. In one study, no prolongation of the QTc interval was observed with fluconazole at a dose of 200 mg daily. Another study, in which fluconazole was administered at doses of 400 mg and 800 mg per day, demonstrated that the use of fluconazole at doses of 400 mg per day or higher significantly increases the plasma concentration of terfenadine when these drugs are used concomitantly. Concomitant use of fluconazole at doses of 400 mg or higher with terfenadine is contraindicated (see the “Contraindications” section). When fluconazole is administered at doses below 400 mg per day concomitantly with terfenadine, the patient’s condition should be closely monitored.

Astemizole: Concomitant use of fluconazole and astemizole may reduce the clearance of astemizole. The resulting increase in astemizole plasma concentrations may lead to QT interval prolongation and, in rare cases, to “pirouette”-type paroxysmal ventricular tachycardia. Concomitant use of fluconazole and astemizole is contraindicated (see the “Contraindications” section).

Pimozide and quinidine: Concomitant use of fluconazole and pimozide or quinidine may result in inhibition of the metabolism of pimozide or quinidine, although no relevant in vitro or in vivo studies have been conducted. Increased plasma concentrations of pimozide or quinidine may cause QT interval prolongation and, in rare cases, lead to the development of “pirouette” paroxysmal ventricular tachycardia. Concomitant use of fluconazole and pimozide or quinidine is contraindicated (see the “Contraindications” section).

Erythromycin: Concomitant use of erythromycin and fluconazole may increase the risk of cardiotoxicity (QT interval prolongation, “pirouette”-type paroxysmal ventricular tachycardia) and, consequently, sudden cardiac death. The combination of these drugs is contraindicated (see the “Contraindications” section).

Concomitant use of fluconazole and the drugs listed below is not recommended.

Halofantrine: Fluconazole may cause an increase in halofantrine plasma concentrations due to CYP3A4 inhibition. Concomitant use of these drugs may increase the risk of cardiotoxicity (QT interval prolongation, paroxysmal ventricular tachycardia of the “pirouette” type) and, consequently, sudden cardiac death. The combination of these drugs should be avoided (see the “Special Considerations for Use” section).

Caution is advised when fluconazole is used concomitantly with the drugs listed below.

Amiodarone: Concomitant use of fluconazole with amiodarone may lead to QT interval prolongation. Fluconazole should be used with caution in combination with amiodarone, especially when high doses of fluconazole (800 mg) are prescribed.

Concomitant use of fluconazole and the medications listed below requires caution and dose adjustment.

  • Effects of Other Medications on Fluconazole.

Interaction studies have shown that oral administration of fluconazole with food, cimetidine, antacids, or subsequent total-body irradiation for bone marrow transplantation has no clinically significant effect on the absorption of fluconazole.

Rifampicin: Concomitant use of fluconazole and rifampicin resulted in a 25% decrease in AUC and a 20% reduction in the half-life of fluconazole. Therefore, for patients taking rifampicin, consideration should be given to increasing the dose of fluconazole.

Hydrochlorothiazide: In a pharmacokinetic interaction study, the concomitant repeated administration of hydrochlorothiazide to healthy volunteers receiving fluconazole increased the plasma concentration of fluconazole by 40%. These interaction parameters do not require changes to the fluconazole dosing regimen for patients who are concurrently receiving diuretics.

  • Effect of fluconazole on other drugs.

Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4. Fluconazole is a potent inhibitor of CYP2C19. In addition to the observed/documented interactions described below, there is a risk of increased plasma concentrations of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4. Therefore, such drug combinations should be used with caution; patients should be closely monitored. The inhibitory effect of fluconazole on these enzymes persists for 4–5 days after administration due to its long half-life (see the “Contraindications” section).

Alfentanil: During concomitant administration of alfentanil at a dose of 20 μg/kg and fluconazole at a dose of 400 mg to healthy volunteers, a twofold increase in AUC10 was observed, possibly due to CYP3A4 inhibition. A dose adjustment of alfentanil may be necessary.

Amitriptyline, nortriptyline: Fluconazole potentiates the effects of amitriptyline and nortriptyline. It is recommended to measure concentrations of 5-nortriptyline and/or S-amitriptyline at the start of combination therapy and after 1 week. If necessary, the dose of amitriptyline/nortriptyline should be adjusted.

Amphotericin B: Concomitant administration of fluconazole and amphotericin B to infected mice with normal immunity and infected mice with impaired immunity yielded the following results: a slight additive antifungal effect in systemic C. albicans infection, no interaction in intracranial Cryptococcus neoformans infection, and antagonism between the two drugs in systemic Aspergillus fumigatus infection. The clinical significance of the results obtained in these studies is unknown.

Anticoagulants: As with other azole antifungals, cases of bleeding (hematomas, epistaxis, gastrointestinal bleeding, hematuria, and melena) in conjunction with prolonged prothrombin time. When fluconazole and warfarin were used concomitantly, a twofold increase in prothrombin time was observed, likely due to inhibition of warfarin metabolism via CYP2C9. Prothrombin time should be carefully monitored in patients who are concurrently taking coumarin anticoagulants or indanedione. An adjustment of the anticoagulant dose may be necessary.

Short-acting benzodiazepines, such as midazolam and triazolam: administration of fluconazole following oral administration of midazolam resulted in a significant increase in midazolam concentrations and an intensification of psychomotor effects. Concomitant administration of 200 mg of fluconazole and 7.5 mg of midazolam orally resulted in a 3.7-fold and 2.2-fold increase in the AUC and half-life of midazolam, respectively. Administration of 200 mg/day of fluconazole and 0.25 mg of triazolam orally resulted in a 4.4-fold and 2.3-fold increase in the AUC and half-life of triazolam, respectively. When fluconazole and triazolam were administered concomitantly, potentiation and prolongation of the effects of triazolam were observed. If a patient undergoing treatment with fluconazole is to be prescribed benzodiazepines concurrently, the dose of the benzodiazepines should be reduced, and the patient’s condition should be closely monitored.

Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and causes a 30% increase in serum carbamazepine levels. There is a risk of carbamazepine toxicity. It may be necessary to adjust the carbamazepine dose depending on its concentration and the drug’s effect.

Calcium channel blockers: Some calcium antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by the CYP3A4 enzyme. Fluconazole may potentially increase the systemic exposure of calcium channel blockers. Close monitoring for the development of adverse reactions is recommended.

Celecoxib: When fluconazole (200 mg daily) and celecoxib (200 mg) were administered concomitantly, the Cmax and AUC of celecoxib increased by 68% and 134%, respectively. When celecoxib and fluconazole are used concomitantly, it may be necessary to reduce the celecoxib dose by half.

Cyclophosphamide: Concomitant use of cyclophosphamide and fluconazole leads to increased levels of bilirubin and creatinine in serum. These drugs may be used concomitantly, taking into account the risk of increased serum bilirubin and creatinine concentrations.

Fentanyl: One fatal case of fentanyl intoxication has been reported due to a possible interaction between fentanyl and fluconazole. Furthermore, a study involving healthy volunteers demonstrated that fluconazole significantly slowed the elimination of fentanyl. Increased fentanyl concentrations may lead to respiratory depression; therefore, the patient’s condition should be closely monitored. A dose adjustment of fentanyl may be necessary.

HMG-CoA reductase inhibitors: Concomitant use of fluconazole and HMG-CoA reductase inhibitors metabolized by CYP3A4 (atorvastatin and simvastatin), or HMG-CoA reductase inhibitors metabolized by CYP2C9 (fluvastatin), increases the risk of myopathy and rhabdomyolysis. If concomitant use of these drugs is necessary, the patient should be closely monitored for symptoms of myopathy and rhabdomyolysis, and creatine kinase levels should be monitored. If creatine kinase levels rise significantly, or if myopathy or rhabdomyolysis is diagnosed or suspected, HMG-CoA reductase inhibitors should be discontinued.

Ibrutinib: Moderate CYP3A4 inhibitors, such as fluconazole, increase the plasma concentration of ibrutinib and the risk of toxicity. If the drug combination cannot be avoided, the dose of ibrutinib should be reduced to 280 mg once daily (2 capsules) to prolong the use of the inhibitor and ensure ongoing clinical monitoring.

Ivacaftor: Concomitant use of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, increased ivacaftor exposure 3-fold, and the exposure to hydroxymethyl-ivacaftor (M1) by 1.9 times. For patients taking moderate CYP3A inhibitors, such as fluconazole and erythromycin, concurrently, a reduction in the ivacaftor dose to 150 mg once daily is recommended.

Olaparib: Moderate CYP3A4 inhibitors, such as fluconazole, increase plasma concentrations of olaparib; their concomitant use is not recommended. If this combination cannot be avoided, olaparib administration should be limited to 200 mg twice daily.

Immunosuppressants (e.g., cyclosporine, everolimus, sirolimus, and tacrolimus).

Cyclosporine: Fluconazole significantly increases the concentration and AUC of cyclosporine. When fluconazole 200 mg/day was administered concomitantly with cyclosporine 2.7 mg/kg/day, a 1.8-fold increase in cyclosporine AUC was observed. These drugs may be used concomitantly provided that the cyclosporine dose is reduced based on its concentration.

Everolimus: Although no in vitro or in vivo studies have been conducted, it is known that fluconazole may increase serum concentrations of everolimus by inhibiting CYP3A4.

Sirolimus: Fluconazole increases sirolimus plasma concentrations, likely by inhibiting sirolimus metabolism by CYP3A4 and P-glycoprotein. These drugs may be used concomitantly provided that the sirolimus dose is adjusted based on drug concentrations and effects.

Tacrolimus: Fluconazole may increase serum tacrolimus concentrations up to 5-fold when administered orally due to inhibition of tacrolimus metabolism by CYP3A4 in the intestine. No significant changes in pharmacokinetics were observed with intravenous administration of tacrolimus. Elevated tacrolimus levels are associated with nephrotoxicity. The dose of tacrolimus for oral administration should be reduced depending on tacrolimus concentrations.

Losartan: Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74), which accounts for most of the angiotensin II receptor antagonism during losartan administration. It is recommended to monitor blood pressure in patients on a regular basis.

Methadone: Fluconazole may increase serum methadone concentrations. When methadone and fluconazole are used concomitantly, adjustment of the methadone dose may be necessary.

Nonsteroidal anti-inflammatory drugs (NSAIDs): When used concomitantly with fluconazole, the Cmax and AUC of flurbiprofen increased by 23% and 81%, respectively, compared with the corresponding values when flurbiprofen was used alone. Similarly, when fluconazole was co-administered with racemic ibuprofen (400 mg), the Cmax and AUC of the pharmacologically active isomer S–(+)-ibuprofen increased by 15% and 82%, respectively, compared with the corresponding values when racemic ibuprofen was administered alone.

Although no specific studies have been conducted, it is known that fluconazole may increase the systemic exposure of other NSAIDs metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). It is recommended to periodically monitor for adverse reactions and toxic effects associated with NSAIDs. Adjustment of the NSAID dose may be necessary.

Phenytoin: Fluconazole inhibits the hepatic metabolism of phenytoin. Concomitant multiple administration of 200 mg of fluconazole and 250 mg of phenytoin intravenously results in a 75% increase in phenytoin AUC24 and a 128% increase in Cmin. When these drugs are used concomitantly, serum phenytoin concentrations should be monitored to prevent the development of phenytoin toxicity.

Prednisone: There has been a reported case in which a patient who had undergone a liver transplant developed acute adrenal insufficiency while taking prednisone; this occurred after discontinuation of a three-month course of fluconazole therapy. Discontinuation of fluconazole likely caused an increase in CYP3A4 activity, leading to accelerated metabolism of prednisone. Patients receiving long-term concomitant therapy with fluconazole and prednisone should be closely monitored to prevent the development of adrenal insufficiency following discontinuation of fluconazole.

Rifabutin: Fluconazole increases rifabutin serum concentrations, resulting in an increase in rifabutin AUC of up to 80%. Cases of uveitis have been reported with the concomitant use of fluconazole and rifabutin. When using this combination of medications, the symptoms of rifabutin toxicity should be taken into account.

Saquinavir: Fluconazole increases the AUC and Cmax of saquinavir by approximately 50% and 55%, respectively, due to inhibition of saquinavir metabolism in the liver by the CYP3A4 enzyme and inhibition of P-glycoprotein. Interactions between fluconazole and saquinavir/ritonavir have not been studied; therefore, they may be more pronounced. A dose adjustment of saquinavir may be necessary.

Sulfonylureas: When administered concomitantly, fluconazole prolongs the half-life of oral sulfonylureas (chlorpropamide, glibenclamide, glipizide, and tolbutamide) when administered to healthy volunteers. Frequent monitoring of blood glucose levels is recommended, and the dose of sulfonylureas should be reduced accordingly when used concomitantly with fluconazole.

Theophylline: In a placebo-controlled drug interaction study, administration of 200 mg of fluconazole daily for 14 days resulted in an 18% decrease in the mean plasma clearance of theophylline. Patients receiving high doses of theophylline or who are at increased risk of theophylline toxicity for other reasons should be monitored for signs of theophylline toxicity. Therapy should be adjusted if signs of toxicity appear.

Tofacitinib: The effects of tofacitinib are enhanced when used concomitantly with drugs that cause moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). Therefore, it is recommended to reduce the dose of tofacitinib to 5 mg once daily when used in combination with these drugs.

Periwinkle alkaloids: Although no relevant studies have been conducted, fluconazole, likely due to CYP3A4 inhibition, may cause an increase in the plasma concentrations of vinca alkaloids (e.g., vincristine and vinblastine), leading to the development of neurotoxic effects.

Vitamin A: It has been reported that in a patient who was simultaneously taking transretinoic acid (the acid form of vitamin A) and fluconazole, experienced central nervous system (CNS) adverse reactions in the form of pseudotumor cerebri; this effect resolved after discontinuation of fluconazole. These medications may be used concomitantly, but the risk of CNS adverse reactions should be kept in mind.

Voriconazole (an inhibitor of CYP2C9, CYP2C19, and CYP3A4): Concomitant use of oral voriconazole (400 mg every 12 hours for 1 day, followed by 200 mg every 12 hours for 2.5 days) and oral fluconazole (400 mg on the first day, followed by 200 mg every 24 hours for 4 days) in 8 healthy male volunteers resulted in an increase in voriconazole Cmax and AUCτ by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. It is unknown whether reducing the dose and/or frequency of voriconazole or fluconazole administration eliminates this effect. When voriconazole is administered following fluconazole, patients should be monitored for the development of adverse effects associated with voriconazole.

Zidovudine: Fluconazole increases the Cmax and AUC of zidovudine by 84% and 74%, respectively, due to a reduction in zidovudine clearance of approximately 45% following oral administration. The half-life of zidovudine was also prolonged by approximately 128% following co-administration of fluconazole and zidovudine. Patients receiving this combination of medications should be monitored for the development of adverse reactions associated with zidovudine use. Consideration should be given to reducing the zidovudine dose.

Azithromycin: In studies investigating the effects of azithromycin and fluconazole on each other’s pharmacokinetics following simultaneous single-dose oral administration at 1,200 mg and 800 mg, respectively, no significant pharmacokinetic interactions were observed.

Oral contraceptives: In pharmacokinetic studies of repeated administration of fluconazole and a combined oral contraceptive, fluconazole at a dose of 50 mg had no effect on hormone levels, whereas with a daily dose of 200 mg of fluconazole, a 40% increase in the AUC of ethinyl estradiol and a 24% increase in the AUC of levonorgestrel were observed. This suggests that repeated administration of fluconazole at the specified doses is unlikely to affect the efficacy of the combined oral contraceptive.

Special Considerations for Use

Dermatophytosis. According to the results of a study of fluconazole for the treatment of dermatophytosis in children, the efficacy of fluconazole does not exceed that of griseofulvin: the overall efficacy rate is less than 20%. Therefore, fluconazole should not be used to treat dermatophytosis.

Cryptococcosis. There is insufficient evidence of fluconazole’s efficacy for the treatment of cryptococcosis in other sites (e.g., pulmonary cryptococcosis and cutaneous cryptococcosis); therefore, there are no dosage recommendations for the treatment of such conditions.

Deep endemic mycoses. There is insufficient evidence of the efficacy of fluconazole for the treatment of other forms of endemic mycoses, such as paracoccidioidomycosis, histoplasmosis, and cutaneous-lymphatic sporotrichosis; therefore, no dosage recommendations are available for the treatment of these conditions.

Renal system. The drug should be used with caution in patients with impaired renal function (see the “Dosage and Administration” section).

Adrenal insufficiency. Ketoconazole is known to cause adrenal insufficiency, and this may also apply to fluconazole, although it is rarely observed. Adrenal insufficiency associated with concomitant treatment with prednisone is described in the section “Interactions with Other Medications and Other Types of Interactions. Effects of Fluconazole on Other Medications.”

Hepatobiliary System. The drug should be used with caution in patients with impaired liver function. The use of fluconazole has been associated with rare cases of severe hepatotoxicity, including fatal cases, primarily in patients with severe underlying medical conditions. In cases where the development of hepatotoxicity was associated with the use of fluconazole, no clear correlation was observed with the total daily dose of the drug, duration of therapy, gender, or age of the patient. Hepatotoxicity caused by fluconazole is usually reversible, and its symptoms resolve after discontinuation of therapy.

Patients who exhibit abnormal liver function test results while taking fluconazole should be closely monitored for the development of more severe liver damage.

Patients should be informed of symptoms that may indicate serious liver damage (severe asthenia, anorexia, persistent nausea, vomiting, and jaundice). In such cases, fluconazole should be discontinued immediately and a physician consulted.

Cardiovascular system. Some azoles, including fluconazole, are associated with QT interval prolongation on the electrocardiogram. Fluconazole prolongs the QT interval by inhibiting the rectifying potassium channel (Ikr). QT interval prolongation caused by other medications (e.g., amiodarone) may be exacerbated by inhibition of the cytochrome P450 CYP3A4 enzyme. Very rare cases of QT interval prolongation and paroxysmal “pirouette”-type ventricular tachycardia have been reported with fluconazole use. These reports involved patients with severe illnesses and a combination of multiple risk factors, such as structural heart disease, electrolyte imbalances, and concomitant use of other medications that affect the QT interval. Patients with hypokalemia and progressive heart failure are at increased risk of life-threatening ventricular arrhythmias and paroxysmal ventricular tachycardia of the “pirouette” type.

Fluconazole should be used with caution in patients at risk of developing arrhythmias. Concomitant use with drugs that prolong the QTc interval and are metabolized by the CYP3A4 enzyme of cytochrome P450 is contraindicated (see the “Contraindications” and “Drug Interactions and Other Interactions” sections).

Halofantrine. Halofantrine is a substrate of CYP3A4 and prolongs the QTc interval when administered at recommended therapeutic doses. Concomitant use of halofantrine and fluconazole is not recommended (see the “Interactions with Other Medications and Other Types of Interactions” section).

Dermatological reactions. Rare cases of exfoliative skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported during treatment with fluconazole. Patients with AIDS are more prone to developing severe skin reactions when taking many medications. If a patient with a superficial fungal infection develops a rash that may be related to fluconazole use, further administration of the drug should be discontinued. If a patient with an invasive/systemic fungal infection develops a skin rash, the patient’s condition should be closely monitored; if bullous rashes or erythema multiforme develop, fluconazole should be discontinued.

Hypersensitivity. In rare cases, anaphylactic reactions have been reported (see the “Contraindications” section).

Cytochrome P450. Fluconazole is a moderate inhibitor of the CYP2C9 and CYP3A4 enzymes. Fluconazole is also a potent inhibitor of the CYP2C19 enzyme. Patients receiving concomitant treatment with fluconazole and drugs with a narrow therapeutic index that are metabolized by CYP2C9, CYP2C19, and CYP3A4 (see the “Drug Interactions and Other Interactions” section).

Terfenadine. Patients should be closely monitored when terfenadine is used concomitantly with fluconazole at a dose of less than 400 mg per day (see the “Contraindications” and “Drug Interactions and Other Interactions” sections).

Use During Pregnancy or Breastfeeding

Pregnancy.

According to an observational study, there is an increased risk of spontaneous abortion in women who received fluconazole during the first trimester of pregnancy.

Numerous congenital anomalies have been reported in newborns (including brachycephaly, auricular dysplasia, excessive enlargement of the anterior fontanelle, hip deformity, and humeroradial synostosis), whose mothers took high doses of fluconazole (400–800 mg/day) for at least three or more months to treat coccidioidomycosis. A causal relationship between fluconazole use and these cases has not been established.

Animal studies have demonstrated reproductive toxicity.

Standard doses of fluconazole and short-term courses of fluconazole therapy should not be used during pregnancy unless absolutely necessary.

High doses of fluconazole and/or prolonged courses of fluconazole therapy should not be used during pregnancy, except for the treatment of life-threatening infections.

Breastfeeding.

Fluconazole passes into breast milk and reaches concentrations similar to those in blood plasma (see the “Pharmacokinetics” section). Breastfeeding may be continued after a single administration of the usual dose of fluconazole, which is 150 mg. Breastfeeding is not recommended with repeated administration of fluconazole or with high doses of fluconazole. The benefits of breastfeeding for the child’s development and health should be weighed against the mother’s clinical need for the medication, as well as the potential adverse effects of the drug or the mother’s underlying condition on the child.

Fertility.

Fluconazole did not affect fertility in male and female rats.

Effect on reaction time when driving or operating machinery

No studies have been conducted on the effect of Difluzol® on the ability to drive or operate machinery.

Patients should be informed of the possibility of dizziness or seizures occurring while taking Difluzol®. If such symptoms develop, driving or operating machinery is not recommended.

Dosage and Administration

Capsules should be swallowed whole. The medication may be taken with or without food.

Adults.

The drug is administered orally at a single dose of 150 mg.

Elderly patients.

In the absence of signs of renal impairment, the usual adult dose is used to treat this patient population.

Renal impairment.

Fluconazole is excreted primarily in the urine in an unchanged form. For a single dose, no dose adjustment is required for this patient population.

Hepatic impairment.

Fluconazole should be used with caution in patients with hepatic impairment, as there is insufficient information regarding the use of fluconazole in this patient population (see the “Special Considerations” and “Adverse Reactions” sections).

Children

The efficacy and safety of the drug for the treatment of genital candidiasis in children have not been established. Currently available information is provided in the “Adverse Reactions” section. If there is an urgent need to administer the drug to adolescents (ages 12 to 17), the usual adult doses should be used.

Overdose

Cases of fluconazole overdose have been reported; these were accompanied by hallucinations and paranoid behavior.

In case of overdose, symptomatic and supportive therapy should be provided, and gastric lavage should be performed if necessary. Fluconazole is largely excreted in the urine; forced diuresis may accelerate the elimination of the drug. A 3-hour hemodialysis session reduces plasma fluconazole levels by approximately 50%.

Side Effects

The most commonly reported (>1/10) adverse reactions were: headache, abdominal pain, diarrhea, nausea, vomiting, elevated alanine aminotransferase (ALT) levels, elevated aspartate aminotransferase (AST) levels, elevated serum alkaline phosphatase levels, rash.

The following classification is used to assess the frequency of adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), frequency unknown (cannot be estimated from the available data).

Blood and lymphatic system disorders.

Uncommon: anemia.

Rare: agranulocytosis, leukopenia, thrombocytopenia, neutropenia.

Immune system disorders.

Rare: anaphylaxis.

Metabolic and nutritional disorders.

Uncommon: decreased appetite.

Rare: hypercholesterolemia, hypertriglyceridemia, hypokalemia.

Psychiatric disorders.

Uncommon: insomnia, drowsiness.

Nervous system disorders.

Common: headache.

Uncommon: convulsions, paresthesia, dizziness, taste disturbances.

Rare: tremor.

Ear and vestibular system disorders.

Uncommon: vertigo.

Cardiac disorders.

Rare: paroxysmal ventricular tachycardia of the “pirouette” type, QT interval prolongation (see the “Special Considerations for Use” section).

Gastrointestinal disorders.

Common: abdominal pain, nausea, diarrhea, vomiting.

Uncommon: constipation, dyspepsia, flatulence, dry mouth.

Hepatobiliary disorders.

Common: elevated alanine aminotransferase (ALT) levels, elevated aspartate aminotransferase (AST) levels, elevated alkaline phosphatase levels (see the “Special Considerations for Use” section).

Uncommon: cholestasis, jaundice, elevated bilirubin levels (see the “Special Considerations for Use” section).

Rare: liver failure, hepatocellular necrosis, hepatitis, hepatocellular damage (see the “Special Precautions for Use” section).

Skin and subcutaneous tissue disorders.

Common: rash (see the “Special Precautions for Use” section).

Uncommon: drug-induced dermatitis (including fixed drug eruption), urticaria, pruritus, increased sweating (see the “Special Precautions for Use” section).

Rare: toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, angioedema, facial swelling, alopecia (see the “Special Considerations for Use” section).

Frequency unknown: drug reaction with eosinophilia and systemic symptoms (DRESS).

Musculoskeletal and connective tissue disorders.

Uncommon: myalgia.

General disorders and administration site conditions.

Uncommon: increased fatigue, malaise, asthenia, fever.

Children.

Frequency and nature of adverse reactions and abnormal laboratory test results in clinical trials involving children compared to those in adults.

Reporting of suspected adverse reactions.

Reporting suspected adverse reactions after the drug’s approval is of great importance. This allows for monitoring the benefit-risk ratio when using this drug. Healthcare professionals should report any suspected adverse reactions in accordance with local laws and regulations.

Shelf life

4 years.

Storage Conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

150 mg capsules, 1 capsule per blister, 1 or 2 blisters per pack; 2 capsules per blister, 1 blister per pack.

Dispensing Category

Over-the-counter – 150 mg capsules, 1 capsule.

Prescription-only – 150 mg capsules, 2 capsules.